Taranenko T. Condition of vessels at systemic diseases of connective tissue and grounding of new methods of treatments

Systemic diseases of connective tissue compose 20% of vascular diseases. Systemic lupus erithematous and systemic scleroderma is a chronic, autoimmune rheumatic diseases with many clinical presentations typically affecting women of childbearing age. The rapid developments in biotechnology of recent years may soon lead to new and specific therapies for patients with systemic diseases of connective tissue. The exact etiology of systemic lupus erithematous and systemic scleroderma is unknown. It is characterized by the production of pathological auto antibodies which adhere to cellular surfaces or form immune complexes which deposit in tissue, leading to end-organ damage with inflammatory mechanisms including complement activation. That may affect the skin, joints, kidneys, lungs, nervous system, serous membranes, and other organs of the body. Atherosclerotic. Aim of work:To assess the effectiveness of diagnosis and treatment of patients with connective tissue diseases,to develop effective methods of therapy, that are able to improve the results of treatment. Objects and methods of research work: these patients have been divided into 3 groups. We have selected 42 patients with systemic lupus erithematous, 44 patients with systemic scleroderma and 22 healthy subjects. We have analyzed the results of treatment of patients with systemic diseases of connective tissue. The following drugs administered for the patients of 1 and 2 group is Esculus-compositum.